Latest ArticlesIn order to control the quality of minodronic acid, this study determined the dimer, [2,5-dihydroxy-3,6-bis(imidazole[1,2-a]pyridin-3-ylmethyl)-2,5-dioxo-1,4,2,5-dioxodiphosphine-3,6-diacyl]bis(phosphonic acid), a relative substance of minodronic acid based on the production process of minodronic acid. It was obtained by the new strategy by reaction of 2-(imidazo[1,2-a]pyridin-3-yl) acetic acid with phosphorus trichloride in methanesulfonic acid(5.5 times amount of substance). The yield was more than 50%, and the purity was not less than 99.0%. The structure of the dimer was confirmed by 1H NMR, 13C NMR, 31P NMR and high resolution mass spectrometry(HRMS), which could be used as a standard for the quality study of minodronic acid.
A novel synthetic process of ethyl (2R,4R)-4-methylpiperidine-2-carboxylate(1), the key intermediate of thrombin inhibitor argatroban, was reported in this paper. 4-Methylcyclohexan-1-one(2) was reacted with hydroxylamine hydrochloride to obtain 4-methylcyclohexan-1-one oxime(3). Compound 3 transformed into 5-methylazepan-2-one(4) through Beckmann rearrangement under p-toluenesulfonamide(p-TSA)/ZnCl2 condition. Compound 4 was treated with cupric bromide to prepare 3-bromo-5-methylazepan-2-one(5). Ethyl 4-methylpiperidine-2-carboxylate(6) was available from 5 via Favorski rearrangement on exposure to sodium ethoxide. Fractionation of 6 under reduced pressure to separate ethyl trans-4-methylpiperidine-2-carboxylate(7). Finally, the target compound 1 was obtained from 7 through resolution by L-(+)-tartaric acid with a purity of 99.58%, a chiral purity of 99.13% and an overall yield of about 9% (based on 2). The new route was easy to operate, safe in production process, which was suitable for industrial production.
In order to control the quality of ivabradine hydrochloride, five related substances were prepared:7,8-dimethoxy-3-propyl-1,3-dihydro-2H-benzo[d]azepin-2-one(related substance A), 3-allyl-7,8-dimethoxy-1,3-dihydro-2H-benzo[d]azepin-2-one(related substance B), 3,3'-(propane-1,3-diyl) bis(7,8-dimethoxy-1,3-dihydro-2H-benzo[d]-azepin-2-one)(related substance C), (S)-[2-[2-[[3-[[[3,4-dimethoxybicyclo[4.2.0]octa-1(6),2,4-trien-7-yl]methyl]-(methyl) amino]propyl]amino]ethyl]-4,5-dimethoxyphenyl]acetic acid(related substance D), 3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)-N-[[(S)-3,4-dimethoxybicyclo[4.2.0]octa-1(6),2,4-triene-7-yl]methyl]-N-methylpropan-1-amine oxide(related substance E). The structures were confirmed by MS and 1H NMR. Among them, both related substance A and B have not found in literature.
In order to perform the quality control of posaconazole, the two process impurities were synthesized, namely 4-[4-[4-[4-[[(3R,5R)-5-[2-fluoro-4-(1H-1,2,4-triazol)phenyl]-5-(1H-1,2,4-triazol-1-ylmethy1)-3-furanyl]-methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(2S,2S)-2-hydroxy-3-pentyl]-1,2,4-triazol-3-one(the related substance A)-and 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,3,4-triazol-1-ylmethy1)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(2S,2S)-2-hydroxy-3-pentyl]-1,2,4-triazol-3-one(the related substance B). The synthesis routes of the related substance A and the related substance B were first reported. The structures of the products were confirmed by 1H NMR and HRMS, which could be used as the references for quality control of posaconazole.
Chimeric antigen receptor(CAR)T cell therapy has become the focus of research in the field of malignant tumor treatment. Prolactin receptor(PRLR) is one of the potential targets for breast cancer treatment, and its overexpression will affect the occurrence and development of breast cancer. In this study, a three-plasmid system[pHIV-green fluorescent protein(GFP), psPAX2, pVSVG] was established to package lentivirus and applied to the newly constructed CAR lentiviral expression vector targeting PRLR. By further optimizing the preparation conditions of lentivirus and measuring the titer of lentivirus, CAR-T cells targeting PRLR were constructed successfully. The results showed that when the mass ratio of PRLR-CAR∶psPAX2∶pVSVG was 3∶2∶1, and mixed with transfection reagent at a mass ratio of 1∶2, the condition for the preparation of lentivirus was the optimality, and the titer could reach 1.88×107 TU/ml after concentration. After infecting human T cells with the lentivirus and screening with a final concentration of 0.5 μg/ml puromycin for two days, CAR-T cells were obtained with the expression positive rates of CD4 and CD8 for 55% and 35%, respectively. And the expression positive rate of PRLR-CAR could be over 50%. The constructed novel CAR-T cells targeting PRLR can provide a reference for the immunotherapy of breast cancer.
Using spherical porous aluminum magnesium silicate(Neusilin® US2) as the carrier, the solid dispersions of trimetazidine hydrochloride with different drug loadings were prepared by solvent dispersion method. Then, these products were characterized by powder X-ray diffraction, differential scanning calorimetry, scanning electron microscopy and dynamic water adsorption. The stability, flowability and compressibility of physical mixtures, different solid dispersions and their mixtures with other excipients were investigated. The results showed that the drug in the solid dispersion prepared with spherical porous aluminum magnesium silicate existed in an amorphous form, and no crystalline form was found in the solid dispersions under the accelerated conditions for 1 month and room temperature for 18 months. Compared with the bulk drug, the fluidity of the solid dispersion was significantly improved, and the compressibility after mixing with other excipients(such as microcrystalline cellulose) was also increased. After mixing the solid dispersion with a drug-carrier ratio of 3∶10 and different amounts of croscarmellose sodium(as a disintegrant), the title tablets were prepared by direct powder compression. The results showed that the dissolution behavior of the solid dispersible tablets with the 2% disintegrant was similar to that of the commercially available trimetazidine hydrochloride tablets(the similarity factor f2 was 59.94).
The effects of chemical penetration enhancers and polymeric surfactant poloxamer 101(P101) on the percutaneous penetration of cannabidiol(CBD) through the excised nude skin were investigated by the methods of premixing and skin pretreatment in this paper. The relevant penetration mechanism was further explored by means of attenuated total reflectance Fourier transform infrared spectroscopy, molecular dynamic simulation and molecular docking. The results showed that the skin pretreatment approach outperformed premixing. The best CBD percutaneous penetration effect was found in the skin pretreatment group of P101 with 1%, reaching a penetration enhancement rate of 12.97. According to the results of molecular dynamic simulation, a stronger interaction was observed between P101 and ceramide NS(lipids in the stratum corneum of the skin), where the binding energy was –8.85 kcal/mol and the cohesive energy density of the lipid bilayer system diminished from 4.15×108 kcal/mol to 3.87×108 kcal/mol, indicating that P101 promoted the skin penetration by disturbing the well-ordered structure of the lipid bilayer system in the stratum corneum and thus increasing its fluidity. This study showed an essential guiding impact for the development of transdermal drug delivery of CBD.
In this study, the chitosan(CS) and polyvinyl alcohol(PVA) based nanofibers were prepared by electrospinning technology in order to load shikonin nanocrystals. The formulation and process parameters were optimized by a single factor experiment with average particle size, polydispersity index, and stability index as the indicators. The diameter of the nanofibers, and the porosity, wettability, water vapor transmission rate and water absorption of the nanofiber membranes were characterized. After optimization, the diameter of the nanofibers was (76.30±18.34)nm; the porosity, contact angle water vapor transmission and water absorption of the membranes were (51.9±5.1)%, (47.35±1.40)°, (0.25±0.01)g·(cm2·24 h)–1 and (180.1±41.7)%, respectively. The observation of scanning electron microscopic images showed that the diameter of the drug-loaded CS/PVA nanofibers was (82.60±22.71)nm. The drug-loaded nanofiber membranes had a utilization rate of (90.97±0.09)% with the porosity of 50.92%. The drug release within 5 h reached more than 90% in 1% Tween-80 solution. In conclusion, this CS/PVA nanofiber membranes loaded with shikonin nanocrystals had the potential applications for wound dressing.
The nanosuspension of phillygenin(1) was prepared by wet grinding technique, then the pellets were prepared with coating liquid consisted of the above nanosuspension, hydroxypropyl methylcellulose, lactose and mannitol by the bottom-spray fluid bed method to improve the stability. The parameters of the coating process were optimized by single factor test and central composite design-response surface methodology. The obtained optimal parameters were as follows: the viscosity of coating solution was 130 mPa·s; the temperature of inlet air was 50 ℃; and the rate of feed was 12 r/min. The average particle size of the optimal nanosuspension and pellets(the redispersed suspension) stored at room temperature for three months were (265.5±5.9) and (220.6±3.8)nm, and polydispersity index were 0.253±0.071 and 0.199±0.069, indicating the stability of nano-sized crystals of 1 was improved by solidification process. The results of in vitro dissolution test showed that the dissolution profiles of nanosuspension and pellets in various pH media were significantly enhanced, compared with the micronized bulk drug.
The tropisetron hydrochloride(TRO) ethosomes with different drug loadings were prepared by ethanol injection method. The particle size, ζ potential, morphology, entrapment efficiency and skin permeability in vitro of the products were characterized. Orthogonal design was adopted to screen the critical excipients in cataplasm. Meanwhile, the TRO ethosomes with different drug loadings were incorporated into cataplasms to solve the problems of inconvenient administration and difficult to continuous delivery. The results of in vitro transdermal permeation study showed that the percutaneous penetration rate and cumulative permeability within 24 h of the cataplasm containing ethosomes with drug loading of 0.36% were 21.66% and (92.45±6.85)μg·cm-2, respectively. Moreover, the in vitro release and in vitro skin permeation of the TRO ethosomal cataplasm and common TRO cataplasm with the same concentration were investigated and compared. It was found that the release of TRO from the ethosomal cataplasm was slower than the common cataplasm, while the transdermal permeation of the ethosomal cataplasm was significantly higher than that of the common cataplasm(P<0.05). The tack and peel adhesion of TRO ethosomal cataplasm was investigated, and the results showed good adhesive properties.